Erdafitinib (ERDA) or ERDA plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma (mUC) and FGFRa

ESMO President: What to watch for at ESMO 2021

Nivolumab plus ipilimumab shows benefit over chemo for unresectable malignant pleural mesothelioma

OncoAlert and ecancer - ESMO 2021 preview

Safety and efficacy of isatuximab plus bortezomib, lenalidomide, and dexamethasone combined therapy for NDMM

Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India

Iberdomide in combination with dexamethasone and daratumumab, bortezomib, or carfilzomib in RRMM patients

Should every transplant eligible NDMM patient receive a transplant?

Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients

Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy

Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients

Idecabtagene vicleucel for relapsed and refractory multiple myeloma